Document Classification

Section Type: RESULTS

Text: Rosiglitazone treated patients also displayed further improvements in glycemic control compared to placebo (HbA (1C) : 6. 4 + or - 0. 7 % vs. 7. 0 + or - 0. 9 %, P < 0. 001) as well as in several cardiometabolic parameters such as lipids (HDL-C : 1. 16 + or - 0. 28 mmol/l vs. 1. 06 + or - 0. 23 mmol/l, P = 0. 003), inflammatory profile (C-reactive protein : 0. 92 mg/l [0. 51-1. 56] vs. 1. 37 mg/l [0. 79-3. 08], P = 0. 02), and adiponectin levels (11. 1 microg/ml [8. 19-17. 9] vs. 4. 65 microg/ml [3. 27-7. 15], P < 0. 001).